Occupational health issues in the pharmaceutical research and development process

Occupational Medicine - State of the Art Reviews

Volumn 12, Issue 1, 1997, Pages 5-27

  Klees, Julia E ^a   Joines, Ron ^b,c  

^a BASF CORPORATION   (United States)

^b SmithKline Beecham   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; BACTERIAL INFECTION; CLINICAL TRIAL; DANGEROUS GOODS; DRUG APPROVAL; DRUG INDUSTRY; HUMAN; HYPERSENSITIVITY; METHODOLOGY; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; PARASITOSIS; RESEARCH; REVIEW; RISK ASSESSMENT; UNITED STATES; VIRUS INFECTION;

ANIMALS; BACTERIAL INFECTIONS; CLINICAL TRIALS; DRUG APPROVAL; DRUG INDUSTRY; HAZARDOUS SUBSTANCES; HUMANS; HYPERSENSITIVITY; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; PARASITIC DISEASES; RESEARCH; RISK ASSESSMENT; UNITED STATES; VIRUS DISEASES;

EID: 33748956352     PISSN: 0885114X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (155)

1. Galen DM: Occupational toxicology in the pharmaceutical industry. In Gad SC (ed): Safety Assessment for Pharmaceuticals. New York, Van Nostrand Reinhold, 1995, pp 301-324.
2. Billstein SA: How the pharmaceutical industry brings an antibiotic drug to market in the United States. Antimicrob Agents Chemother 38:2679-2682, 1994.
3. National Research Council: Biosafety in the Laboratory: Prudent Practices for the Handling and Disposal of Infectious Materials. Washington, DC, National Academy Press, 1989.
4. Centers for Disease Control and Prevention and National Institutes of Health: Biosafety in Microbiological and Biomedical Laboratories, 3rd ed. Washington DC, U.S. Government Printing Office, 1993.
5. National Institutes of Health: Guidelines for research involving recombinant DNA molecules. Federal Register 59:34496-34547, July 5, 1994.
6. Grist NA, Emslie JA: Association of Clinical Pathologists' surveys of infection control in British clinical laboratories. J Clin Pathol 47:391-394, 1994.
7. Pike RM: Laboratory associated infections: Summary and analysis of 3,291 cases. Health Lab Sci 13:105-114, 1976.
8. Committee of Hazardous Biological Substances in the Laboratory: Descriptive epidemiology of occupational infections of laboratory workers. In Biosafety and the Laboratory: Prudent Practices for the Handling and Disposal of Infectious Material. Washington, DC, National Academy Press, 1989, pp 8-12.
9. Gruner E, Bernasconi E, Galeazzi RL, et al: Brucellosis: An occupational hazard for medical laboratory personnel. Report of five cases. Infection 22:33-36, 1994.
10. Harrington JM, Shannon HS: Incidence of tuberculosis, hepatitis, brucellosis and shigellosis in British medical laboratory workers. BMJ i:759-762, 1976.
11. Wedum AG: Laboratory safety in research with infectious aerosols. Public Health Rep 79:619-633, 1964.
12. Liberman DF, Fink R: Containment considerations for the biotechnology industry. Occup Med State Art Rev 6:271-283, 1991.
13. National Institutes of Health: Laboratory safety monograph. Washington, DC, Dept. of Health and Human Services, 1978.
14. Rosenberg J, Hawes Clever L: Medical surveillance of infectious disease endpoints. Occup Med State Art Rev 5:583-605, 1990.
15. Goldman RH: Medical surveillance in the biotechnology industry. Occup Med State Art Rev 6:209-226, 1991.
16. Kalter SS, Millstein CH, Boncyk LH, et al: Tuberculosis in nonhuman primates as a threat to humans. Dev Biol Stand 41:85, 1978.
17. Kaufman AF, Moulthrop JL, Moore RM: A perspective of simian tuberculosis in the United Sates-1972. J Med Primatol 4:278, 1975.
18. Occupational Safety and Health Administration: Occupational exposure to bloodborne pathogens; proposed rule and notice of hearing. Fed Reg 54:23042-23139, 1989.
19. Centers for Disease Control: Occupationally acquired HIV infections in laboratories producing virus concentrates in large quantities; conclusions and recommendations of an expert team convened by the Director of the National Institutes of Health (NIH). MMWR 37:19-22, 1988.
20. Weiss SH, Goedert J, Gartner S, et al: Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. Science 239:68-71, 1988.
21. Petrosillo N, Puro V, Jagger J, Ippolito G: The risks of occupational exposure and infection by human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in the dialysis setting. Italian Multicenter Study on Nosocomial and Occupational Risk of Infections in Dialysis. Am J Infect Control 23:278-285, 1995.
22. Tokars JI, Marcus R, Culver DH, et al: Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 118:13-19, 1993.
23. Henderson DK: HIV-1 in the health care setting. In Mandel GL, Bennett JE, Dolan R (eds): Principles and Practice of Infectious Diseases. 4th ed. New York, Churchill-Livingstone, 1995, pp 2632-2656.
24. Hansen JP, Falconer JA, Hamilton JD, et al: Hepatitis B in a medical center. J Occup Med 23:338-342, 1981.
25. Patz JA, Jodrey D: Occupational health in surgery: Risks extend beyond the operating room. Aust N Z J Surg 65:627-629, 1995.
26. Lanphear BP: Trends and patterns in the transmission of bloodborne pathogens to health care workers. Epidemiol Rev 16:437-450, 1994.
27. Petrosillo N, Puro V, Ippolito G, et al: Hepatitis b virus, hepatitis c virus and human immunodeficiency virus infection in health care workers: A multiple regression analysis of risk factors. J Hosp Infect 30:273-281, 1995.
28. Dreenstag JL, Ryan DM: Occupational exposure to hepatitis B virus in hospital personnel: Infection or immunization. Am J Epidemiol 115:26-39, 1982.
29. Levy BS, Harris JC, Smith JL, et al: Hepatitis B in ward and clinical laboratory employees of a general hospital. Am J Epidemiol 106:330-335, 1977.
30. Kornegay RW, Giddens WE, van Hoosier GL, et al: Subacute nonsuppurative hepatitis associated with hepatitis B virus infection in two cynomologus monkeys. Lab Anim Sci 35:400, 1985.
31. Taber E: Nonhuman primate models for non-A, non-B hepatitis. Cancer Detect Prev 14:221, 1989.
32. Occupational Safety and Health Administration: Bloodborne pathogen standard. 29 CFR 1910.1030.
33. Heller ET, Greer CR: Glove safety: Summary of recent findings and recommendations from health care regulators. South Med J 88:1093-1098, 1995.
34. Roy E, Robillard P: Effectiveness of and compliance to preventive measures against the occupational transmission of human immunodeficiency virus. Scand J Work Environ Health 20:393-400, 1994.
35. Lemon SM, Thomas DL: Drug therapy: Vaccines to prevent viral hepatitis. N Engl J Med 336:196-204, 1997.
36. Hazard Update. Risks from centrifuges. Health Devices 21:290-291, 1992.
37. Fox JG, Lipman NS: Infections transmitted by large and small laboratory animals. Infect Dis Clin North Am 5:131-163, 1991.
38. Fox JG, Taylor NS, Penner JL, et al: Investigation of zoonotic acquired Campylobacter jejuni enteritis with serotyping and restriction endonuclease DNA analysis. J Clin Microbiol 27:2423, 1989.
39. Tribe GW, Fleming MP: Biphasic enteritis in imported cynomologous monkeys infected with Shigella, Salmonella, and Campylobacter species. Lab Anim 17:65, 1983.
40. Kennedy FM, Astbury J, Needham JR, Cheasty T: Shigellosis due to occupational contact with non-human primates. Epidemiol-Infect 110:247-251, 1993.
41. Pucak GJ, Orecutt RP, Judge RJ, et al: Elimination of the Shigella carrier state in rhesus monkeys by trimethoprim-sulfamethoxazole. J Med Primatol 6:127, 1977.
42. Fox JG, Lipman NS: Infections transmitted by large and small laboratory animals. Infect Dis Clin North Am 5:131-163, 1991.
43. Kiel FW, Khan MY: Brucellosis among hospital employees in Saudi Arabia. Infect Control Hosp Epidemiol 14:268-272, 1993.
44. Young EJ: Human brucellosis. Rev Infect Dis 5:321-342, 1983.
45. Polt SS, Dismukes WE, Flint A, et al: Human brucellosis caused by B. canis. Ann Intern Med 97:717, 1982.
46. Blasco JM, Diaz R: Brucella melitensis Rev-1 vaccine as a cause of human brucellosis. Lancet 342:805, 1993.
47. Feign RD, Lobes LA, Anderson LA, et al: Human leptospirosis from immunized dogs. Ann Intern Med 79:777, 1973.
48. Friedmann CT, Spoegel EL, Aaron E, et al: Leptospirosis ballum contracted from pet mice. Calif Med 118:51, 1973.
49. Barkin RM, Guckian JC, Glosser JW: Case report: Infection by Leptospira ballum: A laboratory-associated case. South Med J 67:155, 1974.
50. Stoenner HG, Maclean D: Leptospirosis contracted from Swiss albino mice. Arch Intern Med 101:706, 1958.
51. Rupp ME: Streptobacillus moniliformis endocarditis: Case report and review. Clin Infect Dis 14:769-772, 1992.
52. Taylor AF, Stephenson TG, Giese HA, et al: Rat bite fever in a college student. MMWR 33:318, 1984.
53. Anderson LC, Leary SL, Manning PJ: Rat bite fever in animal research laboratory personnel. Lab Anim Sci 33:292, 1983.
54. Wullenweber M: Streptobacillus moniliformis - a zoonotic pathogen. Taxonomic considerations, host species, diagnosis, therapy, geographical distribution. Lab Anim 29:1-15, 1995.
55. Holmes GP, Hilliard JK, Klontz KC, et al: B virus (herpesvirus simiae) infection in humans: Epidemiologic investigation of a cluster. Ann Intern Med 112:833, 1990.
56. Straus SE: Herpes B virus. In Mandell GL, Bennett JE, Dolin R (eds): Principles and Practices in Infectious Disease. 4th ed. Edinburgh, Churchill-Livingstone, 1995, pp 1379-1382.
57. Davenport DS, Ross SC, Stoltman GA, et al: B virus infection in humans. MMWR 26:453-454, 1989.
58. Centers for Disease Control: Guidelines for the prevention of Herpesvirus simiae (B virus) infection in monkey handlers. MMWR 36:680-689, 1987.
59. Palmer AE: B virus, Herpesvirus simiae: Historical perspective. J Med 16:99-130, 1987.
60. Freifeld AG, Hilliard J, Soutehr J, et al: A controlled seroprevalence survey of primate handlers for evidence of asymptomatic herpes B virus infection. J Infect Dis 171:1031-1034, 1995.
61. Centers for Disease Control: Guidelines for the prevention of Herpesvirus simiae (B virus) infection in monkey handlers. MMWR 36:680-689, 1987.
62. Holmes GP, Chapman LE, Stewart JA, et al: Guidelines for the prevention and treatment of B-virus infections in exposed persons. Clin Infect Dis 20:421-439, 1995.
63. Ward JA, Hilliard JK: B virus specific pathogen free (SPF) colonies of macaques: Issues, surveillance, and results in 1992. Lab Anim Sci 44:222-228, 1994.
64. Center for Disease Control and Prevention: Seroconversion to simian immunodeficiency virus in two laboratory workers. MMWR 41:678-681, 1992.
65. Khabbaz RF, Heneine W, George JR, et al: Brief report: Infection of a laboratory worker with simian immunodeficiency virus. N Engl J Med 330:209-210, 1994.
66. Centers for Disease Control: Anonymous survey for simian immunodeficiency virus (SFV) seropositivity in SIV-laboratory researchers - United States, 1992. MMWR 41:814-815, 1992.
67. Centers for Disease Control: Guidelines to prevent simian immunodeficiency virus infection in laboratory workers and animal handlers. MMWR 37:693-694, 699-704, 1988.
68. Lerche NW, Yee JL, Jennings MB: Establishing specific retrovirus-free breeding colonies of macaques: An approach to primary screening and surveillance. Lab Anim Sci 44:217-221, 1994.
69. Lankas GR, Jensen RD: Evidence of hepatitis A infection in immature rhesus monkeys. Vet Pathol 24:340, 1987.
70. Steffen R: Risk of Hepatitis A in travelers. Vaccine 10:S69-S72, 1992.
71. Hadler SC: Global impact of hepatitis A virus infection: Changing patterns. In Hollinger FB, Lemon SM, Margolis HS (eds): Viral Hepatitis and Liver Disease. Baltimore, Williams & Wilkins, 1991.
72. SmithKline Beecham Pharmaceuticals: Havrix package insert. Philadelphia, 1995.
73. Richter CP, Lehner NDM, Henrickson RV: Primates. In Fox JG (ed): Laboratory Animal Medicine. Orlando, FL, Academic Press, 1984, p 298.
74. Herwaldt BL, Juranek DD: Laboratory-acquired malaria, leishmaniasis, trypanosomiasis, and toxoplasmosis. Am J Trop Med Hyg 48:313-323, 1993.
75. Fayer R, Ungar BLP: Cryptosporidium spp and cryptosporidiosis. Microbiol Rev 50:458, 1986.
76. DiGiacomo RF, Harris NV, Huber NL, et al: Animal exposures and antibodies to Toxoplasma gondii in a university population. Am J Epidemiol 131:729-733, 1990.
77. Parker SL, Holliman RE: Toxoplasmosis and laboratory workers: A case control assessment of risk. Med Lab Sci 49(2):103-110, 1992.
78. Meiklejohn G, Reimer LG, Graves PS, et al: Cryptic epidemic of Q fever in a medical school. J Infect Dis 144:107, 1981.
79. Ruppanner R, Brooks D, Morrish D, et al: Q fever hazards from sheep and goats used in research. Arch Environ Health 37:103, 1982.
80. Ross C, Morrow PS: Q fever: An issue in occupational health and safety? An overview of the methods of control and the effects of Coxiella burnetti on the human host. J R Soc Health 114:151-152, 1994.
81. Bernard KW, Parham GL, Winkler WG, et al: Q fever control measures: Recommendations for research facilities using sheep. Infect Control 3:461, 1982.
82. Ackland JR, Worswick DA, Marmion BP: Vaccine prophylaxis of Q fever. A follow up study of the efficacy of Q-Vax. Med J Aust 160:704-708, 1994.
83. Moore RM, Davis YM, Kaczmarek RG: An overview of occupational hazards among veterinarians with particular reference to pregnant women. Am Ind Hyg Assoc J 54:113-120, 1993.
84. Milligan JE, Sarvaido RJ, Thalken CE: Carcinogens, teratogens, and mutagens: Their impact on occupational health particularly for women in veterinary medicine. J Environ Health 46:19-24, 1983.
85. Barkley WE, Richardson JH: Control of biohazards associated with the use of experimental animals. In Fox JG, Cohen BJ, Loew FM (eds): Laboratory Animal Medicine. Orlando, FL, Academic Press, 1984.
86. Lipman NS, Newcomer CE: Hazard control in the animal research facility. In Liberman DF, Gordon JG (eds): Biohazards Management Handbook. New York, Marcel Dekker, 1989, p 107.
87. Bennett BT, Abee CR, Henrickson R: Non Human Primates in Biomedical Research. San Diego, Academic Press, 1995, pp 193-421.
88. Sessink PJM, DeRoos JHC, Pierik FH, et al: Occupational exposure of animal caretakers to cyclophosphamide. J Occup Med 35:47-52, 1993.
89. Sutherland DE, Smith WA: Chemical hepatitis associated with occupational exposure to halothane in a research laboratory. Vet Hum Toxicol 34:423-424, 1992.
90. Kacergis JB, Jones RB, Reeb CK, et al: Air quality in an animal facility: Particulates, ammonia, and volatile organic compounds. Am Ind Hyg J 57:634-640, 1996.
91. Bland SM, Evans R, Rivera JC: Allergy to laboratory animals in health care personnel. Occup Med State Art Rev 2:525-546, 1987.
92. Botham PA, Lamb CT, Teasdale EL, et al: Allergy to laboratory animals: A follow up study of its incidence and of the influence of atopy and pre-existing sensitization on its development. Occup Environ Med 52:129-133, 1995.
93. Sjostedt L, Willers S, Orbaek P: A follow-up study of laboratory animal exposed workers: The influence of atopy for the development of occupational asthma. Am J Ind Med 24:459-469, 1993.
94. Aoyama K, Ueda A, Manda F, et al: Allergy to laboratory animals: An epidemiological study. Br J Ind Med 49:41-47, 1992.
95. Bryant DH, Boscato LM, Mboloi PN, Stuart MC: Allergy to laboratory animals among animal handlers. Med J Aust 163:415-418, 1995.
96. Eggleston PA, Ansari AA, Adkinson NF, Wood RA: Environmental challenge studies in laboratory animal allergy. Am J Respir Crit Care Med 151:640-646, 1995.
97. Renstrom A, Malmberg P, Larsson K, et al: Allergic sensitization is associated with increased bronchial hyperresponsiveness; a prospective study of allergy to laboratory animals. Eur Resp J 8:1514-1519, 1995.
98. Venables KM, Tee RD, Hawkins ER, et al: Laboratory animal allergy in a pharmaceutical company. Br J Ind Med 45:660-666, 1988.
99. Newill CA, Prenger VL, Fish JE, et al: Risk factors for increased airway responsiveness to methacholine challenge among laboratory animal workers. Am Rev Respir Dis 146:1494-1500, 1992.
100. Venables KM, Upton JL, Hawkins ER, et al: Smoking, atopy, and laboratory animal allergy. Br J Ind Med 45:667-676, 1988.
101. Gordon S, Tee RD, Lowson D, et al: Reduction of airborne allergenic urinary proteins from laboratory rats. Br J Ind Med 49:416-422, 1992.
102. Rivera JC, Bayer RA, Johnson DK: The National Institutes of Health animal handlers medical surveillance program. J Occup Med 26:115-117, 1984.
103. Lutsky II, Kalbfleisch JH, Fink JN: Occupational allergy to laboratory animals: Employer practices. J Occup Med 25:372-376, 1983.
104. Ballantyne B: Hazards in the toxicology laboratory. In Ballantyne B, Marrs T, Turner P (eds): General Toxicology. New York, Van Nostrand Reinhold, 1994, pp 359-366.
105. Newton RW, Browning MCK, Ingal J, et al: Adrenal cortical suppression in workers manufacturing synthetic glucocorticoids. BMJ 1:73-75, 1978.
106. Harrington JM, Stein GF, Rivers RV, DeMorales AV: The occupational hazards of formulating oral contraceptives: A survey of plant employees. Arch Environ Health 33:12-14, 1978.
107. Rylander R, Jacobs RR (eds): Organic Dusts: Exposure, Effects, and Prevention. Boca Raton, FL, CRC Press, 1994.
108. Rodgers B: Health hazards to personnel handling antineoplastic agents. Occup Med State Art Rev 2:513-524, 1987.
109. International Agency for Research on Cancer: Monographs on the evaluation of carcinogenic risk of chemicals to humans. In Vol 26: Some Antineoplastic and Immunosuppressive Agents. Lyon, France, IARC, 1981.
110. ASHP technical assistance bulletin of handling cytotoxic and antineoplastic drugs. Am J Hosp Pharm 47:1033-1049, 1990.
111. Yodaiken RE, Bennett D (eds): OSHA work practice guidelines for personnel dealing with cytotoxic drugs. Am J Hosp Pharm 43:1193-1204, 1986.
112. McDiarmid MA, Emmett EA: Biologic monitoring and medical surveillance of workers exposed to antineoplastic agents. Semin Occup Med 2:109-117, 1987.
113. Ducatman AM, Liberman DF: Worker hazards in the biotechnology industry. In Sullivan JB, Kreiger GR (eds): Hazardous Materials Toxicology. Baltimore, Williams & Wilkins, 1993, pp 556-562.
114. Bukowski JA, Sargent EV, Pena BV: Evaluation of the utility of a standard history questionnaire in assessing the neurologic effects of solvents. Am J Ind Med 22:337-345, 1992.
115. Hathaway GJ, Proctor NH, Hughes JP: Chemical Hazards of the Workplace. 4th ed. New York, Van Nostrand Reinhold, 1996.
116. Garland TO, Patterson MHW: Six cases of acrylamide poisoning. BMJ 4:134-138, 1967.
117. He F, Zhang S, Wang H, et al: Neurological and electroneuromyographic assessment of the adverse effects of acrylamide on occupationally exposed workers. Scand J Work Environ Health 15:125-129, 1989.
118. Cariello NF, Keohavong P, Sanderson JS, Thilly WG: DNA damage produced by ethidium bromide staining and exposure to ultraviolet light. Nucleic Acids Res 16:4157, 1988.
119. Benya TJ, Harbison RD: Aliphatic and alicyclic amines. In Clayton GD, Clayton FE (eds): Patty's Industrial Hygiene and Toxicology. Vol 2, Pt B. New York, John Wiley & Sons, 1994, pp 1140-1149.
120. Amdur ML: Accidental group exposure to acetonitrile. J Occup Med 1:627-633, 1959.
121. Pozzani VC, Carpenter PC, Palm PE: An investigation of the toxicity of acetonitrile. J Occup Med 1:634-642, 1959.
122. Peters RA, Spencer H, Bidstrup PL: Subacute fluoroacetate poisoning. J Occup Med 23:112-113, 1981.
123. Myking AO, Roynstrand E, Laerum OD: Histopathologic laboratories. In Brune DK, Edling C (eds): Occupational Hazards in the Health Professions. Boca Raton, FL, CRC Press, 1989, pp 147-162.
124. Burden AD, O'Driscoll JB, Page FC, Beck MH: Contact hypersensitivity to a new isothiazolinone. Contact Derm 30:179-180, 1994.
125. Knegt-Junk C, Geursen-Reitsma L, Van Joost T: Allergic contact dermatitis from pyridine in Karl Fischer reagent. Contact Derm 28:252, 1993.
126. Chiazze L, Wolf P, Ference LD: An historical cohort study of mortality among salaried research and development workers of the Allied Corporation. J Occup Med 28:1185-1188, 1986.
127. Hoar SK, Pell S: A retrospective cohort study of mortality and cancer incidence among chemists. J Occup Med 23:485-494, 1981.
128. Li FP, Fraumeni JF, Mantel N: Cancer mortality among chemists. J Natl Cancer Inst 43:1159-1164, 1969.
129. Olin GR, Ahlbom A: The cancer mortality among Swedish chemists graduated during three decades. Environ Res 22:154-161, 1980.
130. Belli S, Comba P, De Santis M, et al: Mortality study of workers employed by the Italian National Institute of Health, 1960-1989. Scand J Work Environ Health 18:64-67, 1992.
131. Cordier S: Risk of cancer among laboratory workers. Lancet 335:1097, 1990.
132. Carpenter L, Beral V, Roman E, et al: Cancer in laboratory workers. Lancet 338:1080-1081, 1991.
133. Sasco AJ: Cancer risk in laboratory workers. Lancet 339:684, 1992.
134. Hansson E, Jansa S, Wanda H, et al: Pregnancy outcome for women working in laboratories in some of the pharmaceutical industries in Sweden. Scand J Work Environ Health 6:131-134, 1989.
135. Taskinen H, Kyyronen P, Hemminki K, et al: Laboratory work and pregnancy outcome. J Occup Med 36:311-319, 1994.
136. Mellstrom GA, Wahlberg JE, Maibach HI (eds): Protective Gloves for Occupational Use. Boca Raton, FL, CRC Press, 1994.
137. Hunt LW, Boone-Orke JL, Fransway AF, et al: A medical-center-wide, multidisciplinary approach to the problem of natural rubber latex allergy. J Occup Environ Med 38:765-774, 1996.
138. Occupational Safety and Health Administration: Occupational exposure to hazardous chemicals in laboratories. 29 CFR 1910.1450.
139. Occupational Safety and Health Administration: Hazard communication. 29 CFR 1910.1200.
140. Lee SB, Ryan LJ: Occupational health and safety in the biotechnology industry - A survey of practicing professionals. Am Ind Hyg Assoc J 57:381-386, 1996.
141. National Research Council Regulations. Personal monitoring requirements. 10 CFR 20.202.
142. Mettler FA, Kelsey CA, Ricks RC (eds): Medical Management of Radiation Accidents. Boca Raton, FL, CRC Press, 1990.
143. U.S. Nuclear Regulatory Commission: Regulatory Guide 8.13; Instructions regarding prenatal radiation exposure; Pension 1, November 1975; Office of Standards Development, US NRC, 1975.
144. Stinson MC, Kuritzkes DR, Masse FX: Guidelines for an effective radiation safety program in a human immunodeficiency virus (HIV) laboratory. Health Phys 58:503-505, 1990.
145. Barbanel CS, Ducatman AM, Garston MJ, Fuller T: Laser hazards in research laboratories. J Occup Med 35:369-374, 1993.
146. Barbanel CS: Laser hazards and medical surveillance for laser exposed employees. Occup Environ Med Rep 11:1-8, 1997.
147. American National Standards Institute for the Safe Use of Lasers in Health Care Facilities: ANSI Z136.3, New York, 1996.
148. American National Standards Institute for the Safe Use of Lasers: ANSI Z136.1, New York, 1993.
149. Occupational Safety and Health Administration: Guidelines for laser safety and hazard assessment. Washington, DC, US Dept. of Labor, 1991, OSHA instruction publication 8-1.7.
150. Murray WE: Ultraviolet radiation exposures in a mycobacteriology laboratory. Health Phys 58:507-510, 1990.
151. Occupational Safety and Health Administration: The control of hazardous energy (lockout/tagout). 29 CFR 1910.147.
152. Occupational Safety and Health Administration: Permit-required confined spaces. 29 CFR 1910.146.
153. Wieslander G, Norback D, Edling C: Local cold exposure of the hands from cryosectioning work in histopathological and toxicological laboratories: Signs and symptoms of peripheral neuropathy and Raynaud's phenomenon. Occup Environ Med 53:276-280, 1996.
154. Toren K, Jonsson P, Nilsson R: Vasospastic disease among laboratory technicians using test tube mixers: A report of two cases. Am J Ind Med 21:601-604, 1992.
155. Fredriksson K: Laboratory work with automatic pipettes: A study on how pipetting affects the thumb. Ergonomics 38:1067-1073, 1995.